Table 1.

Patient characteristics and parameters of SCID-hu experiments

PatientAgeGenderSample originImmunophenotypeBM Infiltration (Biopsy)Disease statusPrior therapy*LDH(IU/L)β2M of patients (μg/mL)Cells inoculated (' 106)Human β2M in SCID-hu mice (ng/mL)
173MSpleenCD5+/CD19+/CD20+/CD23±YesRelapsedR-Hyper-CVAD/REV4994.20.5-536.8
265FPBCD5+/CD19+/CD20+/CD23YesRelapsedR-Hyper-CVAD/REV5732.52-532.4
373MLNCD5+/CD19+/CD20+/CD23NoRelapsedRTX/MTX/CTX13003.62-531.0
476MBMCD5+/CD19+/CD20+/CD23YesRelapsedHyper-CVAD/VEL/REV/RTX6402.90.563.6
569MPBCD5+/CD19+/CD20+/CD23YesNewlyNone6567.6214.7
663MPBCD5+/CD19+/CD20+/CD23±YesNewlyNone122415.9242.0
  • Abbreviations: RTX, rituximab; REV, revlimid; VEL, velcade; MTX, methotrexate; CTX, cyclophosphamide; LDH, Lactate dehydrogenase; PB, peripheral blood; LN, lymph node; and BM, bone marrow.

  • * Hyper-CVAD indicates cyclophosphamide/vincristine/doxorubicin/dexamethasone.

  • Human β2M was detected at 3 wk after tumor inoculation.